Maintenance of bronchodilator response for Advair Diskus 250/50 (fluticasone propionate/salmeterol) but not ipratropium/albuterol in patients with COPD

被引：2
|
作者：
Knobil, K [1 ]
Kalberg, C [1 ]
Merchant, K [1 ]
Emmett, A [1 ]
Cicale, M [1 ]
机构：
[1] GlaxoSmithKline, Raleigh, NC USA
来源：
CHEST | 2004年 / 126卷 / 04期
关键词：
D O I：
10.1378/chest.126.4_MeetingAbstracts.807S
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：807S / 807S
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetic Bioequivalence of Two Fluticasone Propionate/Salmeterol Dry Powder Inhalers, OT329 Solis, and Advair Diskus
    Getz, Elise Burmeister
    Carroll, Kevin
    CHEST, 2017, 152 (04) : 768A - 768A
  • [22] Clinical markers of worsening asthma with the fluticasone propionate/salmeterol 100/50 Diskus® (FSC) vs fluticasone propionate (FP) 250mcg alone in patients requiring FP 250 mcg BID for asthma stability
    Dorinsky, PM
    Yancey, SW
    Waiticus-Edwards, K
    Edwards, L
    CHEST, 2003, 124 (04) : 88S - 88S
  • [23] Salmeterol/Fluticasone Propionate via Diskus™ Once Daily versus Fluticasone Propionate Twice Daily in Patients with Mild Asthma not Previously Receiving Maintenance Corticosteroids
    Alexander Chuchalin
    Loretta Jacques
    Lucy Frith
    Clinical Drug Investigation, 2008, 28 : 169 - 181
  • [24] Salmeterol/fluticasone propionate via Diskus™ once daily versus fluticasone propionate twice daily in patients with mild asthma not previously receiving maintenance corticosteroids
    Chuchalin, Alexander
    Jacques, Loretta
    Frith, Lucy
    CLINICAL DRUG INVESTIGATION, 2008, 28 (03) : 169 - 181
  • [25] A randomized, double-blind trial comparing the effect of fluticasone/salmeterol 250/50 to salmeterol on COPD exacerbations in patients with COPD
    Ferguson, Gary
    Anzueto, Antonio
    Fei, Richard
    Emmett, Amanda
    Crater, Glenn
    Knobil, Kate
    Kalberg, Chris
    CHEST, 2007, 132 (04) : 530S - 531S
  • [26] Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD
    Dransfield, Mark T.
    Cockcroft, John R.
    Townsend, Raymond R.
    Coxson, Harvey O.
    Sharma, Sanjay S.
    Rubin, David B.
    Emmett, Amanda H.
    Cicale, Michael J.
    Crater, Glenn D.
    Martinez, Fernando J.
    RESPIRATORY MEDICINE, 2011, 105 (09) : 1322 - 1330
  • [27] Evaluation of airway sGaw in Japanese COPD patients treated with triple therapy using salmeterol/fluticasone propionate 50/250 and tiotropium bromide
    Takaku, Takio
    Saito, Takefumi
    Takeda, Akinori
    Hashimoto, Katsuji
    Kobayashi, Akihiro
    Hayamizu, Tomoyuki
    Hagan, Gerald
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [28] Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting β2-agonists
    Murray, J
    Rosenthal, R
    Somerville, L
    Blake, K
    House, K
    Baitinger, L
    VanderMeer, A
    Dorinsky, P
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2004, 93 (04) : 351 - 359
  • [29] Salmeterol/fluticasone propionate in a Single Inhaler Device versus theophylline plus fluticasone propionate in patients with COPD
    Cazzola, M
    Noschese, P
    Centanni, S
    Santus, P
    Di Marco, F
    Spicuzza, L
    Di Maria, GU
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2004, 17 (03) : 141 - 145
  • [30] Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD
    Vestbo, J
    Soriano, JB
    Anderson, JA
    Calverley, P
    Pauwels, R
    Jones, P
    RESPIRATORY MEDICINE, 2004, 98 (11) : 1045 - 1050
12345